| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 20.6 | 18.5 |
| Gross profit | 6.9 | 5.4 |
| Profit before tax | 3.4 | 6.2 |
| Net income | 3.0 | 4.7 |
| EPS (diluted, $ a share) | $0.92 | $1.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -34.9% |
|---|---|
| Revenue, year on year | +11.0% |
| Gross margin | 33.4% |
| Operating margin | 17.1% |
10-Q filed with the SEC, NASDAQ: PDEX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pro Dex Inc: key numbers
- Share price
- $64.48Close, Nov 16
- Market cap
- $206M
- Shares outstanding
- 3.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pro Dex Inc
All →Pro Dex $8.51M Debt Financing with UMB Bank, N.A.
Pro-Dex, Inc. entered into an amendment to its credit agreement with UMB Bank to consolidate the outstanding principal balances of two term notes into a single $8.51 million Term Note D. The amendment extends the maturity date to November 1, 2031, sets a fixed interest rate of 6.67% per annum, and extends the maturity of its revolving note to December 31, 2028.
- Value
- $8.51M
- Counterparty
- UMB Bank, N.A.
- Term
- through Nov 2031
Pro Dex Capacity Expansion
Pro-Dex subsidiary Advanced Precision Machining (APM) entered into a new lease for a 5,800 square foot industrial unit in Costa Mesa, California, and renewed existing leases for its current manufacturing and warehouse space through September 2030. The new facility more than doubles APM's existing 2,500 square foot footprint, supporting expanded manufacturing and office operations.
- Counterparty
- Salter Family Trust
- Term
- through Sept 2030
Pro Dex Financial Results
Pro-Dex, Inc. reported its fiscal 2027 first quarter results, with net sales increasing 11% to $20.6 million driven by medical device revenue growth. Net income decreased to $3.0 million from $4.7 million in the prior year, primarily due to a significant decrease in unrealized gains on marketable equity investments compared to the year-ago period.
- Term
- Q1 2027
“We are pleased with our first quarter results and continued top line revenue growth.”
Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer
“We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.”
Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer
Pro Dex Other 8-K Filing
Pro-Dex, Inc. entered into a third amendment to its lease agreement with Irvine Business Properties for its executive offices and manufacturing facility in Irvine, California. The amendment extends the lease term to September 30, 2030, and establishes a schedule for 3.5% annual base rent increases starting in October 2027. This filing ensures the company maintains its primary operational and manufacturing footprint for the next four years.
- Counterparty
- Irvine Business Properties
- Term
- through September 30, 2030